SG11202106144VA - Compositions for the delivery of therapeutic agents and methods of use and making thereof - Google Patents
Compositions for the delivery of therapeutic agents and methods of use and making thereofInfo
- Publication number
- SG11202106144VA SG11202106144VA SG11202106144VA SG11202106144VA SG11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA SG 11202106144V A SG11202106144V A SG 11202106144VA
- Authority
- SG
- Singapore
- Prior art keywords
- delivery
- compositions
- making
- methods
- therapeutic agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862778132P | 2018-12-11 | 2018-12-11 | |
US201962846474P | 2019-05-10 | 2019-05-10 | |
US201962857567P | 2019-06-05 | 2019-06-05 | |
US201962889824P | 2019-08-21 | 2019-08-21 | |
US201962916754P | 2019-10-17 | 2019-10-17 | |
PCT/US2019/065288 WO2020123407A1 (en) | 2018-12-11 | 2019-12-09 | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106144VA true SG11202106144VA (en) | 2021-07-29 |
Family
ID=71076135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106144VA SG11202106144VA (en) | 2018-12-11 | 2019-12-09 | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
Country Status (12)
Country | Link |
---|---|
US (3) | US20210290562A1 (en) |
EP (2) | EP4272731A3 (en) |
JP (2) | JP7326445B2 (en) |
KR (1) | KR20210114409A (en) |
CN (2) | CN117695226A (en) |
AU (4) | AU2019398117B2 (en) |
BR (1) | BR112021011087A2 (en) |
CA (1) | CA3119037A1 (en) |
IL (1) | IL283840A (en) |
MX (1) | MX2021006912A (en) |
SG (1) | SG11202106144VA (en) |
WO (1) | WO2020123407A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210290562A1 (en) | 2018-12-11 | 2021-09-23 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
CA3133088A1 (en) * | 2019-03-13 | 2020-09-17 | Michael MILANE | Novel nano-formulation of cannabidiol (cbd) and other cannabinoids for treatment of skin diseases |
CA3151836A1 (en) * | 2019-09-06 | 2021-03-11 | Quicksilver Scientific, Inc. | Microemulsion delivery systems for cannabis extracts and terpenes |
AU2021293891A1 (en) * | 2020-06-17 | 2023-02-02 | Disruption Labs Inc. | Compositions for supplementing products with therapeutic agents and methods of use thereof |
CA3135067A1 (en) * | 2020-10-21 | 2022-04-21 | Corn Products Development, Inc. | Cannabinoid emulsions |
US20220266206A1 (en) * | 2021-02-19 | 2022-08-25 | Gaia Botanicals Llc Dba Bluebird Botanicals | Formulation and process for manufacturing a heat stable oil-in-water emulsion for cannabis beverages in plastic bottles |
WO2022174352A1 (en) * | 2021-02-22 | 2022-08-25 | Cardiol Therapeutics Inc. | Injectable cannabinoid formulations |
EP4319722A1 (en) * | 2021-04-08 | 2024-02-14 | Disruption Labs Inc. | Compositions for supplementing products with therapeutic agents and methods of use thereof |
CA3217973A1 (en) * | 2021-05-03 | 2022-11-10 | Donald L. Simmons | Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof |
IT202100023063A1 (en) * | 2021-09-07 | 2023-03-07 | Herbal Neurocare S R L | Cannabidiol-based composition for the treatment of neuropsychic, inflammatory and pain disorders in humans and animals |
WO2023067509A1 (en) * | 2021-10-18 | 2023-04-27 | Disruption Labs, Inc. | Compositions for supplementing kombucha products with therapeutic agents and methods of making and use thereof |
WO2023194953A1 (en) * | 2022-04-08 | 2023-10-12 | Disruption Labs, Inc. | Compositions for supplementing products with therapeutic agents and methods of use thereof |
CN114681340A (en) * | 2022-04-13 | 2022-07-01 | 肌赋萃生物科技(上海)有限公司 | Lipid barrier repair skin care product containing lipid encapsulation stabilization technology and preparation method thereof |
WO2024031176A1 (en) * | 2022-08-11 | 2024-02-15 | Cardiol Therapeutics Inc. | Stable injectable cannabidiol formulations |
WO2024073849A1 (en) * | 2022-10-07 | 2024-04-11 | Canaquest Medical Corp. | Composition for treating epilepsy |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180713A (en) | 1985-09-27 | 1993-01-19 | Liposome Technology, Inc. | Stabilized liposome/amphotercin B composition and method |
EP0656779B1 (en) | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Submicron emulsions as ocular drug delivery vehicles |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
IL117773A (en) | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
IT1289939B1 (en) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | AQUEOUS PHARMACEUTICAL COMPOSITION INCLUDING A HIGHLY WATER INSOLUBLE ACTIVE SUBSTANCE |
HUP0104255A3 (en) | 1998-11-12 | 2002-12-28 | Pilkiewicz Frank G Princeton J | An pharmaceutical composition suitable for inhalation |
WO2001003668A1 (en) | 1999-07-08 | 2001-01-18 | Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Pulmonary delivery of liposome-encapsulated cannabinoids |
JP2003520210A (en) | 2000-01-05 | 2003-07-02 | イマレックス セラピューティクス, インコーポレイテッド | Pharmaceutical formulations for delivery of drugs with low water solubility |
US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
NZ529544A (en) | 2001-05-31 | 2006-11-30 | Skyepharma Inc | Encapsulation of nanosuspensions in liposomes and microspheres |
JP4537057B2 (en) | 2001-08-14 | 2010-09-01 | テルアビブ・ユニバーシティ・フューチャー・テクノロジー・デベロップメント・エルピー | Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and treatment |
JP4555569B2 (en) | 2001-11-13 | 2010-10-06 | セレーター ファーマシューティカルズ, インコーポレイテッド | Lipid carrier composition having enhanced blood stability |
IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
FR2843023B1 (en) | 2002-07-30 | 2004-09-24 | Sederma Sa | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING KOMBUCHA. |
US8980310B2 (en) | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
JP2007526322A (en) | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | Nanocell drug delivery system |
WO2006073419A2 (en) | 2004-04-01 | 2006-07-13 | Gang Zheng | Lipoprotein nanoplatforms |
WO2006024958A2 (en) | 2004-08-09 | 2006-03-09 | Novimmune S.A. | Cannabinoid compositions and methods of use thereof |
EP2153824A1 (en) | 2004-09-27 | 2010-02-17 | Sigmoid Pharma Limited | Seamless multiparticulate formulations |
ATE412400T1 (en) | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | OIL-IN-WATER EMULSION WITH LOW CATIONIC AGENT CONCENTRATION AND POSITIVE ZETA POTENTIAL |
US20090028931A1 (en) | 2005-01-28 | 2009-01-29 | Bc Cancer Agency | Liposomal compositions for parenteral delivery of agents |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
JP5368793B2 (en) | 2005-07-18 | 2013-12-18 | ユニバーシティ オブ マサチューセッツ ロウエル | Compositions and methods for making and using nanoemulsions |
US8898734B2 (en) | 2005-08-20 | 2014-11-25 | Riverbed Technology, Inc. | Analyzing security compliance within a network |
US8911751B2 (en) | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
ATE544444T1 (en) | 2005-10-11 | 2012-02-15 | Yissum Res Dev Co | COMPOSITIONS FOR NASAL DELIVERY |
US20070116829A1 (en) | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Pharmaceutical Composition with High-Potency Sweetener |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
PT1834635E (en) | 2006-03-13 | 2011-10-13 | Advanced In Vitro Cell Technologies S L | Stable nanocapsule systems for the administration of active molecules |
US7506600B2 (en) | 2006-09-29 | 2009-03-24 | Honda Motor Co., Ltd. | Waterborne vehicle |
WO2008144747A2 (en) | 2007-05-21 | 2008-11-27 | The Regents Of The University Of California | Lipoproteins, lipopeptides and analogs, and methods for making and using them |
US20080296639A1 (en) | 2007-06-01 | 2008-12-04 | Dalsa Corporation | Semiconductor image sensor array device, apparatus comprising such a device and method for operating such a device |
WO2009132277A1 (en) | 2008-04-25 | 2009-10-29 | The Board Of Regents Of The University Of Oklahoma | Inhibition of neovascularization by cerium oxide nanoparticles |
WO2010008762A1 (en) | 2008-07-15 | 2010-01-21 | Robert Lawrence Comstock | Improved emulsifying system for nutraceutical composition |
CN102292076A (en) | 2008-12-11 | 2011-12-21 | 阿帕医药有限公司 | Methods for enhancing stability of polyorthoesters and their formulations |
PL2525782T3 (en) | 2010-01-18 | 2019-09-30 | Concept Medical Research Private Limited | Formulations of nano-carriers and methods of preparing the same |
US20130052259A1 (en) | 2010-02-01 | 2013-02-28 | Yechezkel Barenholz | Liposomes comprising amphipathic drugs and method for their preparation |
JP2013530223A (en) | 2010-07-01 | 2013-07-25 | コバリス,インコーポレイテッド | Compositions and methods for preparing nano-formulations using focused acoustics and systems for nano-delivery |
GB201019434D0 (en) | 2010-11-17 | 2010-12-29 | Isis Innovation | Sonosensitive nanoparticles |
EP2670390A2 (en) | 2011-02-04 | 2013-12-11 | Biocopea Limited | Compostions and methods for treating chronic inflammation and inflammatory diseases |
CN103702988A (en) | 2011-03-25 | 2014-04-02 | 3M创新有限公司 | Fluorinated oxiranes as organic rankine cycle working fluids and methods of using same |
US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
US8808734B2 (en) * | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
CN102929871A (en) | 2011-08-08 | 2013-02-13 | 腾讯科技(深圳)有限公司 | Webpage browsing method and device and mobile terminal |
US20130138615A1 (en) | 2011-11-29 | 2013-05-30 | International Business Machines Corporation | Synchronizing updates across cluster filesystems |
WO2013105101A1 (en) | 2012-01-13 | 2013-07-18 | Department Of Biotechnology | Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same |
DK2804587T3 (en) | 2012-01-19 | 2019-08-12 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | FORMULATION AND PROCEDURE FOR INCREASING THE BIODELESS OF PHARMACEUTICALS |
MX2015000314A (en) | 2012-07-09 | 2015-04-10 | Genentech Inc | Immunoconjugates comprising anti - cd79b antibodies. |
US9622971B2 (en) | 2012-08-17 | 2017-04-18 | Smartek International Llc | Preparation of desiccated liposomes for use in compressible delivery systems |
WO2014100231A1 (en) | 2012-12-18 | 2014-06-26 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
KR101951933B1 (en) * | 2013-03-12 | 2019-02-25 | 주식회사 아리바이오 | Lipid nonomaterials comprising lysophosphatidylcholine or its derivative and Methods for preparing the same |
US10801622B2 (en) | 2013-04-18 | 2020-10-13 | Bal Seal Engineering, Llc | Interlocking face seal assemblies and related methods |
KR101543507B1 (en) | 2013-05-15 | 2015-08-11 | 씨제이헬스케어 주식회사 | A continuous process for preparing microspheres and microspheres prepared thereby |
US9326967B2 (en) | 2013-08-22 | 2016-05-03 | Stephen C. Perry | Vaporizable cannabinoid compositions |
US20150103850A1 (en) | 2013-10-10 | 2015-04-16 | Avago Technologies General Ip (Singapore) Pte. Ltd. | Communication Device Utilizing An Interrupting Alignment Pattern |
CA2926797A1 (en) | 2013-10-14 | 2015-04-23 | Nanosphere Health Sciences, Llc | Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers |
AU2014347807A1 (en) * | 2013-10-31 | 2016-05-26 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
CA2931039C (en) | 2013-11-20 | 2022-07-12 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
WO2015117011A1 (en) | 2014-01-31 | 2015-08-06 | Pocket Tea, Llc | Tea composition for oral administration |
US9766473B1 (en) | 2014-02-03 | 2017-09-19 | Automation Engineering, Inc. | Automated UV calibration, motorized optical target and automatic surface finder for optical alignment and assembly robot |
US20150258114A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of substance abuse using ibogaine |
US20160271252A1 (en) | 2014-05-29 | 2016-09-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US20160367496A1 (en) | 2014-05-29 | 2016-12-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US20170224634A1 (en) | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US11224660B2 (en) | 2014-05-29 | 2022-01-18 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
WO2015200864A1 (en) | 2014-06-27 | 2015-12-30 | Crowley Kenton L | Buccal and sublingual cannabinoid formulations and method of making the same |
US10307397B2 (en) | 2014-07-28 | 2019-06-04 | Concept Matrix Solutions | Oral dissolvable film that includes plant extract |
WO2016044813A1 (en) | 2014-09-18 | 2016-03-24 | Virun, Inc. | Pre-spray emulsions and powders containing non-polar compounds |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
US20160081975A1 (en) | 2014-09-18 | 2016-03-24 | Virun, Inc. | Soft gel compositions and pre-gel concentrates |
WO2016044805A1 (en) | 2014-09-18 | 2016-03-24 | Virun, Inc. | Soft gel compositions and pre-gel concentrates |
US10016363B2 (en) | 2014-09-18 | 2018-07-10 | Virun, Inc. | Pre-spray emulsions and powders containing non-polar compounds |
CA2968929A1 (en) | 2014-11-26 | 2016-06-02 | One World Cannabis Ltd | Synergistic use of cannabis for treating multiple myeloma |
US20180289665A1 (en) | 2014-12-07 | 2018-10-11 | One World Cannabis Ltd | Use of cannabis to treat migraine |
CA3050535C (en) | 2014-12-15 | 2021-11-09 | Richard Clark Kaufman | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals |
AU2015369546A1 (en) | 2014-12-21 | 2017-07-13 | One World Cannabis Ltd | Cannabis-based extracts and topical formulations for use in skin disorders |
US20160184228A1 (en) * | 2014-12-31 | 2016-06-30 | Eric Morrison | UNILAMELLAR NIOSOMES HAVING HIGH Kow PHARMACOLOGICAL COMPOUNDS SOLVATED THEREIN AND A METHOD FOR THE PREPARATION THEREOF |
WO2017054071A1 (en) | 2015-01-21 | 2017-04-06 | Willinsky Michael | Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler |
WO2016144376A1 (en) | 2015-03-10 | 2016-09-15 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
CA2982250A1 (en) * | 2015-03-19 | 2016-09-22 | One World Cannabis Ltd. | Preparations of cannabis emulsions and methods thereof |
WO2016160822A1 (en) | 2015-03-30 | 2016-10-06 | Verily Life Sciences Llc | Functionalized nanoparticles, methods and in vivo diagnostic system |
US9835558B2 (en) | 2015-04-20 | 2017-12-05 | Chunqiu Zhang | Aggregation-induced emission luminogen having an peptide sequence and its uses thereof |
AU2016261707A1 (en) | 2015-05-13 | 2017-12-07 | One World Cannabis Ltd | Use of cannabis to treat fibromyalgia, methods and compositions thereof |
AU2016267585C1 (en) | 2015-05-28 | 2023-02-16 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US20200121616A1 (en) * | 2015-06-09 | 2020-04-23 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
AU2016276563A1 (en) | 2015-06-11 | 2018-01-04 | One World Cannabis Ltd | Novel cannabinoid combination therapies for multiple myeloma (MM) |
KR20160149398A (en) | 2015-06-18 | 2016-12-28 | 조셉 종을 정 | A Vitamin C delivery system and liposomal composition thereof |
AU2016293834A1 (en) | 2015-07-10 | 2018-02-01 | Asociación Centro de Investigación Cooperativa en Biociencias- CIC bioGUNE | MCJ inhibitors for use in treating drug-induced diseases and conditions |
WO2017031261A1 (en) | 2015-08-20 | 2017-02-23 | Mewa Singh | Polyphenolic polymer to make water-insoluble molecules become water-soluble |
CA3003120A1 (en) | 2015-10-26 | 2017-05-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabinoid formulations |
CA3020798A1 (en) | 2016-04-12 | 2017-10-19 | Scott SCHANEVILLE | Ingestible films having substances from hemp or cannabis |
US20190201372A1 (en) | 2016-04-12 | 2019-07-04 | Habi Pharma Pty Ltd | Liposomal preparation and methods of treatment |
EP3463304A4 (en) * | 2016-05-24 | 2020-01-08 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
EP3462885A4 (en) | 2016-05-27 | 2020-01-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US20180255801A1 (en) | 2016-05-27 | 2018-09-13 | Pocket Tea, Llc | Compositions containing tea, tea-like or other non-tobacco leaf-like material |
US10765658B2 (en) | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
EP3515444A4 (en) * | 2016-09-26 | 2020-06-03 | Reyoung (Suzhou) Biology Science & Technology Co., Ltd | Composition for treating ocular diseases and methods of usage and making |
IL248149B (en) | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
WO2018080933A1 (en) | 2016-10-24 | 2018-05-03 | Pellficure Pharmaceuticals Inc. | Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione |
EP3554272A4 (en) | 2016-12-16 | 2021-01-06 | Flavorsense | Dried flakes with active ingredients |
MX2019009642A (en) | 2017-02-15 | 2019-11-11 | Molecular Infusions Llc | Formulations. |
CA3062814C (en) | 2017-04-27 | 2023-11-14 | Insys Development Company, Inc. | Stable cannabinoid formulations |
WO2018204326A1 (en) | 2017-05-01 | 2018-11-08 | Mj Wooly Corporation | Methodology and formulation for creating a powder of an encapsulated cannabis-based component embedded in a polymer matrix |
WO2018205038A1 (en) | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
AU2018273410A1 (en) * | 2017-05-26 | 2020-01-16 | Altum Pharmaceuticals Inc. | Biphasix cannabinoid delivery |
EP3417846A1 (en) | 2017-06-19 | 2018-12-26 | Gifar Srl | Food and/or nutraceutical composition |
WO2018237109A1 (en) | 2017-06-23 | 2018-12-27 | Yale University | Nanomaterials with enhanced drug delivery efficiency |
CN110996911B (en) | 2017-06-26 | 2023-01-17 | 福多兹制药公司 | Aprepitant nano-microcapsule preparation as well as method and application thereof |
US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
US20210212946A1 (en) | 2018-01-03 | 2021-07-15 | Icdpharma Ltd. | Solid self-emulsifying cannabinoid compositions |
WO2019135224A1 (en) | 2018-01-03 | 2019-07-11 | Icdpharma Ltd. | Taste-enhanced cannabinoid submicron emulsion syrup compositions |
CN114173797A (en) * | 2018-08-20 | 2022-03-11 | 埃克索运营公司 | Product infused with cannabis with enhanced cannabinoid profile user experience |
US20210290562A1 (en) | 2018-12-11 | 2021-09-23 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
-
2019
- 2019-12-09 US US16/646,528 patent/US20210290562A1/en active Pending
- 2019-12-09 JP JP2021533365A patent/JP7326445B2/en active Active
- 2019-12-09 CN CN202311475429.1A patent/CN117695226A/en active Pending
- 2019-12-09 WO PCT/US2019/065288 patent/WO2020123407A1/en unknown
- 2019-12-09 CN CN201980089918.9A patent/CN113382719B/en active Active
- 2019-12-09 SG SG11202106144VA patent/SG11202106144VA/en unknown
- 2019-12-09 BR BR112021011087-9A patent/BR112021011087A2/en unknown
- 2019-12-09 MX MX2021006912A patent/MX2021006912A/en unknown
- 2019-12-09 EP EP23189384.3A patent/EP4272731A3/en active Pending
- 2019-12-09 CA CA3119037A patent/CA3119037A1/en active Pending
- 2019-12-09 AU AU2019398117A patent/AU2019398117B2/en active Active
- 2019-12-09 KR KR1020217021487A patent/KR20210114409A/en not_active Application Discontinuation
- 2019-12-09 EP EP19897051.9A patent/EP3840730B1/en active Active
-
2021
- 2021-03-24 US US17/211,616 patent/US11260033B2/en active Active
- 2021-05-12 AU AU2021203006A patent/AU2021203006B2/en active Active
- 2021-05-12 AU AU2021203013A patent/AU2021203013C1/en active Active
- 2021-06-09 IL IL283840A patent/IL283840A/en unknown
-
2022
- 2022-01-06 US US17/569,967 patent/US20220241217A1/en active Pending
-
2023
- 2023-08-02 JP JP2023126261A patent/JP2023159144A/en active Pending
- 2023-08-04 AU AU2023210660A patent/AU2023210660A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4272731A2 (en) | 2023-11-08 |
US20210251917A1 (en) | 2021-08-19 |
CN113382719A (en) | 2021-09-10 |
AU2021203006A1 (en) | 2021-06-10 |
US20220241217A1 (en) | 2022-08-04 |
CA3119037A1 (en) | 2020-06-18 |
US11260033B2 (en) | 2022-03-01 |
US20210290562A1 (en) | 2021-09-23 |
IL283840A (en) | 2021-07-29 |
EP3840730A4 (en) | 2021-12-22 |
WO2020123407A1 (en) | 2020-06-18 |
CN117695226A (en) | 2024-03-15 |
EP4272731A3 (en) | 2024-02-14 |
AU2021203006B2 (en) | 2023-06-08 |
EP3840730A1 (en) | 2021-06-30 |
CN113382719B (en) | 2023-10-31 |
JP2022512235A (en) | 2022-02-02 |
AU2021203013A1 (en) | 2021-06-10 |
AU2023210660A1 (en) | 2023-08-24 |
MX2021006912A (en) | 2021-08-24 |
KR20210114409A (en) | 2021-09-23 |
JP2023159144A (en) | 2023-10-31 |
JP7326445B2 (en) | 2023-08-15 |
AU2019398117A1 (en) | 2021-04-08 |
AU2019398117B2 (en) | 2021-04-15 |
BR112021011087A2 (en) | 2021-08-31 |
EP3840730B1 (en) | 2023-09-20 |
AU2021203013C1 (en) | 2023-08-10 |
AU2021203013B2 (en) | 2023-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283840A (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
IL276464A (en) | Methods and compositions for therapeutic protein delivery | |
IL268999A (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
PL3386484T3 (en) | Compositions and methods for delivery of therapeutic agents | |
IL273959A (en) | Methods and compositions for the treatment of rare diseases | |
EP3813853A4 (en) | Compositions for drug delivery and methods of use thereof | |
EP3512554A4 (en) | Platelet compositions and methods for the delivery of therapeutic agents | |
IL274578A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
EP3740576A4 (en) | Therapeutic compositions and methods of making and using the same | |
ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
SI3768284T1 (en) | Compositions of entrecoccus flagellin for use in therapy | |
EP3773654C0 (en) | Polypharmaceutical drug compositions and related methods | |
EP3773747A4 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
IL272495A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
IL271596A (en) | Compositions for drug delivery and methods of use thereof | |
PL3867282T3 (en) | Conjugates of hyaluronic acid and aminobisphosphonates and the therapeutic use thereof | |
EP3781194A4 (en) | Compositions and methods for the selective delivery of therapeutic and imaging agents | |
EP3856892A4 (en) | Compositions and methods for the in situ delivery of therapeutic and diagnostic agents | |
IL282671A (en) | Therapeutic methods and compositions | |
GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
EP3773732A4 (en) | Methods and compositions for delivery of a therapeutic agent | |
GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
GB201813312D0 (en) | Compounds and their therapeutic use |